ALLEGRA PILL 180MG
ALLEGRA PILL 180MG - 10 tablets
Security policy (edit with Customer reassurance module)
Delivery policy (edit with Customer reassurance module)
Return policy (edit with Customer reassurance module)
- seasonal allergic rhinitis (to reduce symptoms) - tablets, 120 mg;
- Chronic idiopathic urticaria (to reduce symptoms) - tablets, 180 mg.
Dosage and administration
Tablets are intended for ingestion.
Recommended dose of fexofenadine with seasonal allergic rhinitis for adults and children 12 years and older makes 120 mg once a day before food.
Recommended dose of fexofenadine with chronic urticaria for adults and children 12 years of age and older, it is 180 mg once a day before meals.
Patients at risk
Studies in special risk groups (elderly patients, patients with renal and hepatic insufficiency) showed that they do not require correction of the dosage regimen.
In placebo-controlled clinical trials, the most frequent (≥1% - <10%) observed undesirable effects were headache (7.3%), drowsiness (2.3%), dizziness (1.5%) and nausea 1.5%. When taking fexofenadine, the frequency of the above adverse effects was similar to that of taking placebo.
In placebo-controlled studies with a frequency of less than 1% (equally when taking fexofenadine and placebo) and with post-marketing use of the drug were weakness, insomnia, nervousness and sleep disorders or unusual dreams (paroniria), such as nightmares; tachycardia, palpitations; diarrhea.
In rare cases ((≥0.01% - <0.1%), exanthema, urticaria, pruritus and other hypersensitivity reactions were observed, such as angioedema, difficulty breathing, shortness of breath, skin hyperemia, systemic Anaphylactic reactions.
- hypersensitivity to any of the components of the drug;
- lactation period;
- children's age (up to 12 years).
- in patients with chronic renal and hepatic insufficiency, as well as in elderly patients (lack of clinical experience in this category of patients);
- in patients with cardiovascular diseases, including in the anamnesis (antihistamines can cause heartbeat and tachycardia).
Use during pregnancy and lactation
There is not enough data on the use of fexofenadine in pregnant women. Limited animal studies have shown no signs of adverse effects on pregnancy, fetal development, childbirth, and postnatal development. Fexofenadine should not be used during pregnancy.
Data on the content of fexofenadine in breast milk when it is taken by nursing women is not available. However, when taking terfenadine, its penetration into breast milk of lactating women was observed. Therefore, the use of fexofenadine during the lactation period is not recommended.
Application for violations of the liver
Use with caution in chronic liver failure. Correction of the dosing regimen is not required.
Application for violations of kidney function
Use with caution in chronic renal failure. Correction of the dosing regimen is not required.
Use in children
Contraindicated in children under 12 years.
Use in elderly patients
Use of the drug with caution for elderly patients (lack of clinical experience with this category of patients). Correction of the dosing regimen is not required.
It is recommended that the time interval between taking fexofenadine and antacids containing aluminum or Magnesium hydroxide is at least 2 hours.
For use in children from 6 to 11 years old pills are available 30 mg.
Influence on ability to drive motor transport and control mechanisms
When taking the drug, it is possible to perform work that requires a high concentration of attention and speed of psychomotor reactions (with the exception of patients with non-standard reaction). Therefore, it is recommended to check the individual response to fexofenadine before engaging in such activities.
Symptoms: dizziness, drowsiness, and dry mouth. Healthy volunteers took single doses up to 800 mg, and course doses up to 690 mg 2 times a day for 1 month or 240 mg 2 times a day for 1 year without any significant adverse effects compared to placebo. The maximum tolerated dose for fexofenadine has not been established.
Treatment: in case of overdose, it is recommended to conduct gastric lavage, taking Activated carbon, if necessary, symptomatic and supportive therapy. Hemodialysis is ineffective.
When combined with fexofenadine Erythromycin or Ketoconazole, the concentration of fexofenadine in plasma increases by 2-3 times, but this is not associated with a significant lengthening of the QTc interval. There were no significant differences in the incidence of adverse effects with the use of these drugs in monotherapy and in combination. Animal studies have shown that the aforementioned increase in plasma concentrations of fexofenadine is probably associated with improved absorption of fexofenadine and a decrease in its biliary excretion or secretion into the lumen of the gastrointestinal tract.
The interaction between fexofenadine and Omeprazole is not observed.
Does not interact with drugs that metabolize in the liver.
Acceptance of aluminum or magnesium-containing antacids 15 minutes before taking fexofenadine results in a decrease in the bioavailability of the latter as a result of apparently binding in the gastrointestinal tract.
Terms and conditions of storage
At a temperature not higher than 25 ° С. Keep out of the reach of children!